Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Has Average Price Target of $21.00

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $21.00.

Several research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $12.00 on Friday. The company has a 50 day moving average price of $13.19 and a 200 day moving average price of $13.32. The stock has a market capitalization of $349.50 million, a P/E ratio of -4.98 and a beta of 0.93. Enanta Pharmaceuticals has a fifty-two week low of $7.05 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million for the quarter, compared to analysts’ expectations of $16.76 million. On average, research analysts forecast that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $6,660,000. Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter worth approximately $15,873,698. Jupiter Topco LLC purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $53,252,000. Janus Henderson Group PLC grew its holdings in Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares during the period. Finally, BlackRock Inc. acquired a new position in Enanta Pharmaceuticals during the second quarter worth approximately $47,304,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.